or Try an Advanced Search...

    Technical Analysis for ANIX - Anixa Biosciences, Inc.

    Grade Last Price % Change Price Change
    F 3.12 2.46% 0.08
    ANIX closed down 2.4 percent on Wednesday, November 20, 2024, on 39 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Flat Down Down
    Historical ANIX trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 2.46%
    Wide Bands Range Expansion 2.46%
    Oversold Stochastic Weakness 2.46%
    200 DMA Resistance Bearish 0.00%
    Bullish Engulfing Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Resistance Bearish 2.30%
    Doji - Bullish? Reversal 2.30%
    Wide Bands Range Expansion 2.30%
    Older End-of-Day Signals for ANIX ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 2 hours ago
    Up 1% about 2 hours ago
    Down 3% about 21 hours ago
    Fell Below Previous Day's Low about 22 hours ago
    Possible Inside Day about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ANIX Chart by TradingView
    Basic chart:

    Profile

    Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Emerging Technologies Cancer Treatment Gene Therapy Leukemia Blood Test Amines Chimeric Antigen Receptor Immune Response

    Is ANIX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
    Nov 8 Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Nov 6 Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Oct 31 Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
    Oct 28 Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Oct 24 US Penny Stocks To Consider In October 2024
    Oct 16 Anixa Biosciences administers second CAR-T dose in ovarian cancer trial
    Oct 15 Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
    Oct 7 Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development
    Sep 30 Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
    See more ANIX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.13
    52 Week Low 2.145
    Average Volume 80,401
    200-Day Moving Average 3.13
    50-Day Moving Average 3.26
    20-Day Moving Average 3.39
    10-Day Moving Average 3.22
    Average True Range 0.24
    RSI (14) 41.86
    ADX 19.28
    +DI 21.81
    -DI 16.43
    Chandelier Exit (Long, 3 ATRs) 3.47
    Chandelier Exit (Short, 3 ATRs) 3.66
    Upper Bollinger Bands 3.94
    Lower Bollinger Band 2.83
    Percent B (%b) 0.19
    BandWidth 32.63
    MACD Line -0.05
    MACD Signal Line 0.00
    MACD Histogram -0.0557
    Fundamentals Value
    Market Cap 96.53 Million
    Num Shares 31.7 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -9.52
    Price-to-Sales 680.79
    Price-to-Book 5.87
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.30
    Resistance 3 (R3) 3.32 3.25 3.26
    Resistance 2 (R2) 3.25 3.19 3.24 3.24
    Resistance 1 (R1) 3.15 3.15 3.12 3.13 3.23
    Pivot Point 3.08 3.08 3.07 3.07 3.08
    Support 1 (S1) 2.98 3.02 2.95 2.96 2.86
    Support 2 (S2) 2.92 2.98 2.91 2.85
    Support 3 (S3) 2.81 2.92 2.83
    Support 4 (S4) 2.79